How does the chinese gene recreate the glory of the past
01
The chinese gene has been acquired
In recent days, chongqing's new product, acquired at a cost of $1. 1,476 million, has completed the business change registration process and obtained a business licence. In order to optimize the industrial layout, prior to that, the chinese great genome board agreed to use its own funds to acquire the shares held by the related parties in chongqing xin. Following the completion of the transaction, the chinese gene held 100 per cent interest in the new product of chongqing, which was included in the company's consolidated statement。
Founded in 2023, chongqing's new product focuses on pathological diagnostics, with core technologies in the fields of immunochemicals (ihc), multi-immuno-fluorescents, temporal and temporal pathology and intellectual pathology. It serves critical clinical and scientific scenes such as pathology diagnostics, oncology precisions, diagnostics and drug research and development through the export of high-specific diagnostic reagents and accompanying solutions。
In the past two years, chinese genetics days have not worked well. Since 2022, china's great genetic company has experienced a continuous decline; net profits jumped sharply in 2024 and lost $900 million, and in 2025 it lost more than $600 million。
Even so, the chinese gene continues to be carefully considered and a new investment landscape has been put in place to enhance industrial synergy and integration of industrial chain resources and accelerate business upgrading and strategic landing。
In addition to the above-mentioned acquisitions, the great gene of china had previously announced its intention to participate as a limited partner in the investment to establish the great biomedicine industry fund. The total contribution of the investment fund is rmb 300 million, of which the chinese gene is intended to contribute rmb 87 million as a limited partner with its own funds。
The investment direction will focus on life sciences and precision medicine and their upstream and downstream long-term projects, with the main subdivisions being: medical devices, in vitro diagnostics, medical and health data, synthetic organisms, cell and gene therapy, and research and development of new biological medicines。
02
Tighten your belt
All the way to sea
At a recent performance statement meeting, the chinese gene had revealed signs that it was about to tighten its belt。
The chinese gene community has made it clear that by 2026, significant capital expenditure will be strictly controlled, non-essential expenditure will be dynamically monitored, receivables will be increased and credit risk will be strictly controlled. At the same time, the chinese gene will be ready for operations with weak profitability, sustained losses and limited development prospects, indicating that closure and reorganization will be undertaken in a timely manner to optimize the business structure and to achieve the concentration of resources in core niche operations。
Taken together, the sharp fall in income from reproductive health, precision medical testing, infection prevention and so forth has been an important factor in the decline in china's genetic performance in recent years. Volatility in market demand, increased competition in industry, and declining prices for end-of-service and product products all pose considerable challenges to the chinese gene。
The good signal is that last year the chinese genetic losses narrowed considerably, and some of the plates have begun to reverse。
In 2025, the medical detection of genetic precision and infection prevention and control operations in china grew. Of this total, 1,588 million yuan, representing an increase of 19. 45 per cent over the same year, were generated by the integrated solution for precision medical testing, and 95 million yuan, representing an increase of 30. 29 per cent over the same year, while the income of the ptseq series of products based on the high-throughput sequence (tngs) technology doubled over the same period。
Multigroups and synthetics generate $668 million, which is almost the same as the same period last year. The increase in income from single-cell sequencing operations was significant, at an estimated 87 per cent over the same period。
For the great chinese genes, innovation is urgent if we are to emerge from the great canyon of performance and regain the glory of the past。
The chinese gene uses intellectualization and globalization as two important targets。
With regard to the development of overseas markets, the main anchors are now the “one way forward” and the brics countries, deepening their localized operational strategies。
At present, the great chinese gene has offshore centres and core laboratories in europe, latin america and other regions, operating in more than 100 countries and regions around the world, and there are over 3,000 co-operative medical and scientific institutions in europe, the americas and asia and the pacific。
The great gene programme of china continues to integrate local supply chains and explore synergies with other industrial chains of overseas chinese enterprises to deepen localization. The product strategy will focus in the future on core products such as prenatal testing and whole genome sequencing in overseas markets。
In addition, the chinese gene will enhance the construction of large data and digital intelligence, continuously advance the development of a multi-module multimodule database for precision medicine, integrate large data and smart technology based on the advantages of the multi-group autonomy platform, build a new paradigm of smart medicine for “genetic testing + health management” and speed up the layout health management course by providing a full-process health management service covering health screening, risk assessment, individualized intervention and monitoring throughout the process。
New initiatives are not meant to translate into tangible results. It may take some time for the chinese gene to actually get out of its head。
